EMBECTA CORP
EMBCNASDAQTrading Snapshot
- Day Range
- $4.82 – $4.98
- 52-Week Range
- $2.77 – $15.55
- Volume
- $2.71B
- Avg Volume
- $3.02B
- Shares Outstanding
- 59.3M
- Next Earnings
- Oct 23, 2026
Fundamentals Snapshot
- Annual Revenue
- $1.08B
- Last Q Revenue
- $272M
- P/E Ratio
- 2.6
- P/S Ratio
- 0.3x
- EPS (TTM)
- $1.90
- Dividend Yield
- 11.92%
Why Investors Own EMBC
- ✓High-growth profile — revenue up -2.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 52% gross margin and 6% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About EMBECTA CORP
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Embecta Corp. (EMBC) Q3 2026 Earnings Call Transcript
Embecta Corp. (EMBC) Q3 2026 Earnings Call August 7, 2026 8:00 AM EDTCompany ParticipantsPravesh Khandelwal - VP & Head of Investor RelationsDevdatt...
Embecta Corp. 2026 Q3 - Results - Earnings Call Presentation
2026-08-07. The following slide deck was published by Embecta Corp.
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers AVITA Medical (NASDAQ:RCEL) stock rose 58.4% to $7.53 during Friday's regular session. The company's market cap stands at $146.1 million. As per the press release, Q2 earnings came out yesterday.
Embecta (NASDAQ:EMBC) Jumps 9% on Strong Fiscal Q3 Earnings Beat
Embecta (EMBC) beats Q3: EPS $0.56 vs $0.27 est., revenue $271.7M vs $259.6M. Stock up 9.4% pre-market on strong earnings.
Embecta Raises FY2026 Adj EPS Guidance from $1.55-$1.75 to $1.80-$1.90 vs $1.59 Est; Affirms FY2026 Sales Guidance of $1.015B-$1.035B vs $1.021B Est
Embecta (NASDAQ:EMBC) raises FY2026 Adj EPS guidance from $1.55-$1.75 to $1.80-$1.90 vs $1.59 analyst estimate. Affirms FY2026 sales outlook from $1.015 billion-$1.035 billion to $1.015 billion-$1.035 billion vs $1.021
Have We Entered A Stealth Bear Market?
For months I've had an uneasy feeling about the sustainability of this great bull run.